{
    "root": "a76d7bdc-6652-4db6-825a-74d464a47697",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "KISQALI FEMARA CO-PACK",
    "value": "20250225",
    "ingredients": [],
    "indications": "kisqali femara co-pack , co-packaged product containing ribociclib , kinase inhibitor , letrozole , aromatase inhibitor , indicated : adjuvant treatment adults hormone receptor ( hr ) -positive , human epidermal growth factor receptor 2 ( her2 ) -negative stage ii iii early breast cancer high risk recurrence . ( 1 ) initial endocrine-based therapy treatment adults hr-positive , her2-negative advanced metastatic breast cancer therapy . ( 1 )",
    "contraindications": "kisqali femara co-pack tablets taken combination orally without food . ( 2 ) early breast cancer kisqali recommended starting dose : 400 mg orally ( two 200 mg tablets ) taken daily 21 consecutive days followed 7 days kisqali treatment . ( 2.1 ) advanced metastatic breast cancer kisqali recommended starting dose : 600 mg orally ( three 200 mg tablets ) taken daily 21 consecutive days followed 7 days kisqali treatment . ( 2.1 ) kisqali dose interruption , reduction , and/or discontinuation may required based individual safety tolerability . ( 2.2 ) femara : 2.5 mg ( one tablet ) continuously 28-day cycle . ( 2.1 )",
    "warningsAndPrecautions": "kisqali femara co-pack dispensed carton total 28 days therapy . carton contains individual ribociclib letrozole products follows : kisqali ( ribociclib ) tablets : 200 mg tablets . light greyish violet , round , curved beveled edge , debossed “ ric ” one side “ nvr ” side . femara ( letrozole ) tablets : 2.5 mg tablets . dark yellow , round , slightly biconvex , beveled edges , imprinted letters “ fv ” one side “ cg ” side . kisqali femara co-pack cartons : ndc 0078-0923-61 – carton 3 blister packs ( 63 tablets total ) – blister pack contains 7-day supply 21 tablets ( 200 mg per tablet ) ( 600 mg daily dose ) kisqali plus one 28-tablet count bottle femara ndc 0078-0916-61 – carton 3 blister packs ( 42 tablets total ) – blister pack contains 7-day supply 14 tablets ( 200 mg per tablet ) ( 400 mg daily dose ) kisqali plus one 28-tablet count bottle femara ndc 0078-0909-61 – carton 1 blister pack ( 21 tablets total ) – blister pack contains 21-day supply 21 tablets ( 200 mg per tablet ) ( 200 mg daily dose ) kisqali plus one 28-tablet count bottle femara store refrigerated 2°c 8°c ( 36°f 46°f ) . excursions permitted 2°c 15°c ( 36°f 59°f ) . dispensing , patients may store room temperature 20°c 25°c ( 68°f 77°f ) 2 months . store tablets original blister pack .",
    "adverseReactions": "known hypersensitivity active substance ( letrozole ) , excipients femara . refer femara prescribing information .",
    "indications_original": "KISQALI FEMARA CO-PACK, a co-packaged product containing ribociclib, a kinase inhibitor, and letrozole, an aromatase inhibitor, is indicated: for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. ( 1 ) as initial endocrine-based therapy for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer therapy. ( 1 )",
    "contraindications_original": "KISQALI FEMARA CO-PACK tablets are taken in combination orally with or without food. ( 2 ) Early Breast Cancer KISQALI recommended starting dose: 400 mg orally (two 200 mg tablets) taken once daily for 21 consecutive days followed by 7 days off KISQALI treatment. ( 2.1 ) Advanced or Metastatic Breast Cancer KISQALI recommended starting dose: 600 mg orally (three 200 mg tablets) taken once daily for 21 consecutive days followed by 7 days off KISQALI treatment. ( 2.1 ) KISQALI dose interruption, reduction, and/or discontinuation may be required based on individual safety and tolerability. ( 2.2 ) FEMARA: 2.5 mg (one tablet) continuously for a 28-day cycle. ( 2.1 )",
    "warningsAndPrecautions_original": "KISQALI FEMARA CO-PACK is dispensed in a carton for a total of 28 days of therapy.\n                  Each carton contains individual ribociclib and letrozole drug products as follows:\n                  \n                     KISQALI (ribociclib) Tablets:\n                  \n                  200 mg tablets.\n                  Light greyish violet, round, curved with beveled edge, debossed with “RIC” on one side and “NVR” on the other side.\n                  \n                     FEMARA (letrozole) Tablets:\n                  \n                  2.5 mg tablets.\n                  Dark yellow, round, slightly biconvex, with beveled edges, imprinted with the letters “FV” on one side and “CG” on the other side.\n                  \n                     KISQALI FEMARA CO-PACK Cartons:\n                  \n                  \n                     NDC 0078-0923-61 – Carton of 3 blister packs (63 tablets total) – each blister pack contains a 7-day supply of 21 tablets (200 mg per tablet) (600 mg daily dose) of KISQALI plus one 28-tablet count bottle of FEMARA\n                     NDC 0078-0916-61 – Carton of 3 blister packs (42 tablets total) – each blister pack contains a 7-day supply of 14 tablets (200 mg per tablet) (400 mg daily dose) of KISQALI plus one 28-tablet count bottle of FEMARA\n                     NDC 0078-0909-61 – Carton of 1 blister pack (21 tablets total) – each blister pack contains a 21-day supply of 21 tablets (200 mg per tablet) (200 mg daily dose) of KISQALI plus one 28-tablet count bottle of FEMARA\n                  \n                  Store refrigerated at 2°C to 8°C (36°F to 46°F). Excursions permitted between 2°C and 15°C (36°F and 59°F).\n                  After dispensing, patients may store at room temperature at 20°C to 25°C (68°F to 77°F) for up to 2 months. \n                  Store tablets in the original blister pack.",
    "adverseReactions_original": "Known hypersensitivity to the active substance (letrozole), or to any of the excipients of FEMARA. Refer to FEMARA Prescribing Information."
}